Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Terran Biosciences secures intellectual property for psychedelic prodrugs

By Brian Buntz | February 3, 2023

Terran BiosciencesTerran Biosciences, a neurology and psychiatry-focused startup, has announced the publication of patent applications under the Patent Cooperation Treaty (PCT) for its novel prodrugs of DMT, 5-MeO-DMT and MDMA.

Claim of superior pharmacokinetics

The company believes the prodrugs have superior pharmacokinetic profiles compared to the unmodified forms of these Schedule I substances. Additionally, it believes it can make DMT and 5-MeO-DMT orally active through its proprietary prodrug approach. Visceral monoamine oxidase (MAO), a digestive enzyme, inactivates the drug when taken orally in its standard form.

DMT, the primary psychoactive ingredient in ayahuasca, is traditionally consumed with an MAO inhibitor (MAOI) such as harmine or harmaline. This approach is unlikely to become widely adopted in clinical practice as a result of potential side effects such as nausea, vomiting and blood pressure changes.

Although injectable, inhaled, buccal and sublingual delivery methods are also possible for DMT and 5-MeO-DMT, Terran notes in a press release that it “believes oral medications would provide the best use profile for patients.”

A Phase 1 study at Yale found that DMT has promise in treating major depressive disorder. A Phase 2 study is in the works.

Possible long-acting form of MDMA

Classic MDMA, conversely, is orally active. The Multidisciplinary Association for Psychedelic Studies (MAPS) Executive Director Rick Doblin recently predicted that the FDA would approve MDMA-assisted therapy for PTSD in 2024. The organization has conducted two Phase 3 studies of the drug for that indication.

Terran believes its MDMA prodrug could be the first long-acting form of MDMA. The company notes that clinical trials exploring the use of the drug as an adjunct to psychotherapy often use an MDMA redosing strategy for some patients.

Last year, Terran acquired central nervous system assets from Concert Pharmaceuticals (Nasdaq:CNCE). Terran plans to develop deuterated compounds with potential applications across several different psychiatric and neurological conditions.

While public interest in psychedelics has been on the upswing recently, public psychedelic therapy companies have struggled with falling valuations in recent years.


Filed Under: Psychiatric/psychotropic drugs
Tagged With: Terran Biosciences
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE